Prospects of using sodium-glucose co-transporter-2 (SGLT-2) inhibitors in patients with metabolic-associated fatty liver disease (MAFLD)-Reference-Cited by-同舟云学术

Prospects of using sodium-glucose co-transporter-2 (SGLT-2) inhibitors in patients with metabolic-associated fatty liver disease (MAFLD)

Published:2023-10-27 Issue:5 Volume: Page:8-37
ISSN:2415-7252
Container-title:Diabetes Obesity Metabolic Syndrome
language:uk
Short-container-title:DOMS

Author:

Kostitska Iryna^ORCID,Protas Nadia^ORCID,Petrovska Liliia^ORCID

Abstract

Metabolic dysfunction-associated fatty liver disease (MAFLD) is recognised worldwide as a serious health problem, given the global prevalence of about 30% of the world population and high incidence of nonalcoholic steatohepatitis (NASH), which has reached epidemic levels in the 12%-21% of people with type 2 diabetes mellitus (DM). In patients with comorbidity of type 2 DM, atherosclerotic cardiovascular disease (ASCVD), visceral obesity (VO), insulin resistance syndrome (IRS) the frequency of MAFLD is 70%. For this reason a modern, complex and patient-oriented approach to the treatment of MAFLD is of paramount importance, which can simultaneously treat several disorders by preventing interaction between underlying causes of NASH in patients with type 2 DM. The growing burden of morbidity, therapeutic inertia of primary care physicians and highly specialized gastroenterologists, endocrinologists regarding early diagnostics of NASH in people with type 2 DM and VO often leads to incomplete treatment of MAFLD manifestations. Nowadays SGLT-2 inhibitors present an innovative class of hypoglycemic drugs which have improved the glucose-centric approach to the therapy of type 2 DM combined with organ-protective properties. The data obtained from epoch-making controlled clinical trials and clinical practice presents an opportunity of new clinical horizons regarding the hepatoprotective properties of SGLT-2 inhibitors. In this review the efficacy, safety and prospects of using SGLT-2 in patients with MAFLD were evaluated.

Publisher

Ukrainian Diabetology Association

Reference186 articles.

1. Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016; 64: 73–84. Available from: https://doi.org/10.1002/hep.28431.

2. Younossi ZM, Wong G, Anstee QM, Henry L. The Global Burden of Liver Disease. Clin Gastroenterol Hepatol. 2023 Jul; 21 (8): 1978-1991. Available from: https://doi.org/10.1016/j.cgh.2023.04.015.

3. Stefan N, Cusi K. A global view of the interplay between nonalcoholic fatty liver disease and diabetes. Lancet Diabetes Endocrinol. 2022; 10 (4): 284–296. Available from: https://doi.org/10.1016/S2213-8587(22)00003-1.

4. Alonso-Peña M, Del Barrio M, Peleteiro-Vigil A, Jimenez-Gonzalez C, Santos-Laso A, Arias-Loste MT, et al. Innovative Therapeutic Approaches in Non-Alcoholic Fatty Liver Disease: When Knowing Your Patient Is Key. Int J Mol Sci. 2023 Jun 27; 24(13): 10718. Available from: https://doi.org/ 10.3390/ijms241310718.

5. Fadieienko GD, Chereliuk NI, Galchinskaya VY. Metabolic diseases and non-alcoholic fatty liver disease - features of the composition of gut microbiota. Problems of Endocrine Pathology. 2020; 74 (4): 99-105. Urkainian. Available from: https://doi.org/10.21856/j-PEP.2020.4.13.